SANA

Sana Biotechnology Reports Third Quarter 2023 Financial Results and Business Updates

Retrieved on: 
Wednesday, November 8, 2023

Enrollment in the ARDENT Phase 1 study continues, and initial clinical data are expected in 2023 and more robust data expected in 2024.

Key Points: 
  • Enrollment in the ARDENT Phase 1 study continues, and initial clinical data are expected in 2023 and more robust data expected in 2024.
  • Initial HIP proof of concept data are expected in 2023 and 2024.
  • Sana is developing SC451, a hypoimmune-modified stem-cell derived pancreatic islet cell therapy for patients with type 1 diabetes.
  • A discussion of non-GAAP measures, including a reconciliation of GAAP and non-GAAP measures, is presented below under “Non-GAAP Financial Measures.”

Sana Biotechnology Announces Five Presentations at the 65th American Society of Hematology Annual Meeting

Retrieved on: 
Thursday, November 2, 2023

SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that five abstracts will have poster presentations at the 65th American Society of Hematology Annual Meeting to be held December 9-12, 2023 in San Diego, CA.

Key Points: 
  • SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that five abstracts will have poster presentations at the 65th American Society of Hematology Annual Meeting to be held December 9-12, 2023 in San Diego, CA.
  • Details of the poster presentations are as follows:

Sana Biotechnology Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with a 2024 Operating Burn under $200M

Retrieved on: 
Tuesday, October 10, 2023

The company will reduce near-term spend on its fusogen platform for in vivo gene delivery, which postpones the planned SG299 IND and decreases its expected forward operating burn.

Key Points: 
  • The company will reduce near-term spend on its fusogen platform for in vivo gene delivery, which postpones the planned SG299 IND and decreases its expected forward operating burn.
  • We plan to present clinical data in these areas at various times across 2023 and 2024,” said Steve Harr, President and CEO of Sana.
  • Sana expects 2024 operating cash burn to be below $200 million, allowing the current cash position to extend further into 2025.
  • Sana will leverage its existing allogeneic manufacturing expertise and continue development of its GMP manufacturing facility in Bothell, Washington.

Sana Biotechnology to Present at September 2023 Investor Conferences

Retrieved on: 
Wednesday, August 30, 2023

SEATTLE, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at five investor conferences in September.

Key Points: 
  • SEATTLE, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at five investor conferences in September.
  • Steve Harr will present at Citi’s 18th Annual BioPharma Conference at 10:30 a.m.
  • Steve Harr will present at the 2023 Wells Fargo Healthcare Conference at 2:15 p.m.
  • Nate Hardy will present at the 2023 Cantor Global Healthcare Conference at 10:55 a.m.

Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates

Retrieved on: 
Thursday, August 3, 2023

Sana is developing SC451, a hypoimmune-modified stem-cell derived islet cell therapy for patients with type 1 diabetes.

Key Points: 
  • Sana is developing SC451, a hypoimmune-modified stem-cell derived islet cell therapy for patients with type 1 diabetes.
  • Sana expects initial data later this year from an investigator-sponsored trial transplanting hypoimmune-modified primary human islet cells into type 1 diabetes patients.
  • Second, Sana created a humanized mouse model with immune cells from a diabetic person and transplanted pancreatic islet cells derived from the diabetic person’s stem cells.
  • A discussion of non-GAAP measures, including a reconciliation of GAAP and non-GAAP measures, is presented below under “Non-GAAP Financial Measures.”

Sana Biotechnology Highlights Preclinical Data from Hypoimmune and Fusogen Platforms at the International Society for Stem Cell Research (ISSCR) 2023 Annual Meeting

Retrieved on: 
Friday, June 16, 2023

SEATTLE, June 16, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced preclinical data from six presentations, including two oral presentations, at the International Society for Stem Cell Research (ISSCR) 2023 Annual Meeting.

Key Points: 
  • SEATTLE, June 16, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced preclinical data from six presentations, including two oral presentations, at the International Society for Stem Cell Research (ISSCR) 2023 Annual Meeting.
  • “Our leading presence at ISSCR showcased key preclinical data generated from our programs using our hypoimmune and fusogen platforms,” said Doug Williams, Ph.D., Sana’s President of Research and Development.
  • We also shared data demonstrating in vivo delivery of various genetic payloads to human hematopoietic stem/progenitor cells, highlighting an important capability with the fusogen platform.
  • The studies showed that these fully differentiated SC-islets can be delivered intramuscularly with robust function and without the need for bioscaffolding.

Sana Biotechnology to Present at June 2023 Investor Conferences

Retrieved on: 
Wednesday, May 31, 2023

SEATTLE, May 31, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in June.

Key Points: 
  • SEATTLE, May 31, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in June.
  • The presentations will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer.
  • Sana will present at the Jefferies Healthcare Conference at 9:30 a.m.
  • Sana will present at the Goldman Sachs 44th Annual Global Healthcare Conference at 10:00 a.m. PT on Monday, June 12, 2023.

Sana Biotechnology Announces Preclinical Data Published in Nature Biotechnology Demonstrating its Hypoimmune-Engineered Cells Escape Immune Detection and Survive While Remaining Fully Functional

Retrieved on: 
Monday, May 8, 2023

SEATTLE, May 08, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that Nature Biotechnology has published a paper titled “Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques.” The preclinical studies published in this paper used Sana’s hypoimmune (HIP) technology to engineer HIP-modified allogeneic cells to escape immune detection in the absence of immune suppression. In vivo studies in fully immunocompetent non-human primates (NHPs) demonstrated that HIP-modified allogeneic cells survived without immunosuppression for the length of the studies (16 weeks and >40 weeks). An additional humanized mouse study showed that HIP-modified induced pluripotent stem cells (iPSCs) that are differentiated into pancreatic islet cells were immune evasive and ameliorated diabetes in vivo.

Key Points: 
  • “These published data in rigorous translational models that closely imitate the human immune system support our previous findings, most importantly that HIP-modified allogeneic cells avoid immune recognition and rejection without immune suppression.
  • In NHPs first receiving HIPallo cells, no cellular immune activation or killing of HIPallo cells was observed after cell transplantation.
  • The HIPallo cells survived with no evidence of immune recognition despite this immune response to wtallo cells.
  • Subsequent transplantation of HIPallo cells showed survival and no cellular immune response to HIPallo cells despite the previous immune activation to and killing of wtallo cells.

Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates

Retrieved on: 
Monday, May 8, 2023

Sana is developing SC451, a hypoimmune-modified stem-cell derived islet cell therapy for patients with type 1 diabetes.

Key Points: 
  • Sana is developing SC451, a hypoimmune-modified stem-cell derived islet cell therapy for patients with type 1 diabetes.
  • Expect initial data later this year from an investigator-sponsored trial transplanting hypoimmune-modified primary human islet cells into type 1 diabetes patients.
  • The goal of the study is to show cell survival and immune evasion without the need for any immunosuppression.
  • A discussion of non-GAAP measures, including a reconciliation of GAAP and non-GAAP measures, is presented below under “Non-GAAP Financial Measures.”

Sana Biotechnology to Present at May 2023 Investor Conferences

Retrieved on: 
Wednesday, May 3, 2023

SEATTLE, May 03, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in May.

Key Points: 
  • SEATTLE, May 03, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in May.
  • The presentations will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer and Nate Hardy, Sana’s Chief Financial Officer.
  • Steve Harr will present at the BofA Securities 2023 Healthcare Conference at 2:20 p.m. PT on Tuesday, May 9, 2023.
  • The webcasts will be accessible on the Investor Relations page of Sana’s website at https://sana.com/ .